SCYX
SCYNEXIS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.93
−0.25%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.96
From 52W high−55.74%
Volume10779.00
Market cap$39.10M
P/E (TTM)—
P/S (TTM)2.0x
Div yield—
Key dataNov 4, 2026
Open
$3.96
From 52W high
−55.74%
Volume
10779.00
Market cap
$39.10M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.3x
P/E (TTM)
—
RSI (14)
42.7
MomentumView details →
1D Return
−0.25%
YTD Return
−23.32%
SummaryUpdated Jun 1, 2026
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company founded in 1999 and headquartered in Jersey City, New Jersey. The company went public in May 2014 and specializes in developing antifungal treatments, with a particular focus on addressing serious and life-threatening fungal infections. SCYNEXIS has successfully brought its first commercial product, BREXAFEMME, to market and continues to develop its lead compound ibrexafungerp for various fungal indications through clinical trials and strategic partnerships.
Similar companies
Latest newsMore news →
SCYNEXIS announced topline results from the Phase 1 single- and multiple-ascending-dose trial of intravenous SCY-247.13d agoSCYNEXIS announced Phase 1 study results for SCY-770, a novel oral direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD), reporting it was well tolerated with a favorable safety profile in healthy adult participants.29d agoSCYNEXIS Inc signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) worth up to $214 million to develop SCY-247, with an initial base period of approximately $18.5 million for a Phase 2 study.37d ago